Abstract
THE EMPHASIS in research on Parkinson's disease should be put on factors that lead to cell death, the study of genetic susceptibility, improvements in drug therapy, and the identification of clinically useful markers. This was the major advice a broad spectrum of neurologic researchers and clinicians handed to the National Institute of Neurological Disorders and Stroke (NINDS) after a 2-day workshop on research priorities related to Parkinson's disease held in Washington, DC. The workshop was convened at the request of Congress. Initially, said Thomas Chase, MD, chief of the experimental therapeutics branch of the NINDS, Congress wanted the institute to hold a consensus meeting to recommend the best ways to treat the disorder. But, he said, there is not yet enough knowledge to reach a consensus. As an alternative, the NINDS, along with two sister National Institutes of Health (NIH) agencies—the National Institute on Aging, Bethesda, Md, and the National
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
